Intralesional ethanol for an unresectable epithelial inclusion cyst.

monthly administration of bevacizumab or ranibizumab for years. This case dramatically demonstrates the ability of such a switch to promptly resolve this leakage, albeit in the absence of any short-term visual acuity improvement, presumably because of outer retinal atrophy and scar. Further follow-up of similar cases seems warranted. In addition, whether similar but earlier intervention with aflibercept might avoid visual acuity loss earlier in the disease and whether cases initially unresponsive to aflibercept might show similar responses when switching to another anti-VEGF medication such as ranibizumab will require additional study.